JP2003515323A - 抗 体 - Google Patents

抗 体

Info

Publication number
JP2003515323A
JP2003515323A JP2001538975A JP2001538975A JP2003515323A JP 2003515323 A JP2003515323 A JP 2003515323A JP 2001538975 A JP2001538975 A JP 2001538975A JP 2001538975 A JP2001538975 A JP 2001538975A JP 2003515323 A JP2003515323 A JP 2003515323A
Authority
JP
Japan
Prior art keywords
scfv
dam
nucleotide sequence
cells
scfv antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001538975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003515323A5 (cg-RX-API-DMAC7.html
Inventor
キングズマン，アラン
キングズマン，スーザン・メアリ
ベビントン，クリストファー・ロバート
キャロル，マイルズ・ウィリアム
エラード，フィオナ・マーガレット
マイヤーズ，ケヴィン・アラン
Original Assignee
オックスフォード バイオメディカ（ユーケイ）リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB1999/003859 external-priority patent/WO2000029428A2/en
Priority claimed from GB0003527A external-priority patent/GB0003527D0/en
Priority claimed from GB0005071A external-priority patent/GB0005071D0/en
Application filed by オックスフォード バイオメディカ（ユーケイ）リミテッド filed Critical オックスフォード バイオメディカ（ユーケイ）リミテッド
Publication of JP2003515323A publication Critical patent/JP2003515323A/ja
Publication of JP2003515323A5 publication Critical patent/JP2003515323A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C07K16/1145—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2001538975A 1999-11-18 2000-11-13 抗 体 Pending JP2003515323A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB99/03859 1999-11-18
PCT/GB1999/003859 WO2000029428A2 (en) 1998-11-18 1999-11-18 5t4 tumour-associated antigen for use in tumour immunotherapy
GB0003527A GB0003527D0 (en) 2000-02-15 2000-02-15 Antibodies
GB0003527.9 2000-02-15
GB0005071.6 2000-03-02
GB0005071A GB0005071D0 (en) 2000-03-02 2000-03-02 Antibodies
PCT/GB2000/004317 WO2001036486A2 (en) 1999-11-18 2000-11-13 Scfv antibodies against disease associated molecules

Publications (2)

Publication Number Publication Date
JP2003515323A true JP2003515323A (ja) 2003-05-07
JP2003515323A5 JP2003515323A5 (cg-RX-API-DMAC7.html) 2007-12-20

Family

ID=27255534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001538975A Pending JP2003515323A (ja) 1999-11-18 2000-11-13 抗 体

Country Status (7)

Country Link
US (4) US7074909B2 (cg-RX-API-DMAC7.html)
EP (1) EP1242456B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003515323A (cg-RX-API-DMAC7.html)
CN (1) CN1423660A (cg-RX-API-DMAC7.html)
AU (1) AU1290001A (cg-RX-API-DMAC7.html)
CA (1) CA2391925A1 (cg-RX-API-DMAC7.html)
WO (1) WO2001036486A2 (cg-RX-API-DMAC7.html)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006132352A1 (ja) * 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2を含有する医薬組成物
JP2008506389A (ja) * 2004-07-13 2008-03-06 セル ジェネシス インコーポレイテッド Ａａｖベクター組成物および免疫グロブリンの発現の増強のための方法ならびにその使用方法
US7993642B2 (en) 2003-12-12 2011-08-09 Chugai Seiyaku Kabushiki Kaisha Anti-MPL antibodies
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
US8945543B2 (en) 2005-06-10 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
WO2015133484A1 (ja) * 2014-03-04 2015-09-11 国立大学法人徳島大学 腎臓疾患に関するマーカー及びその利用
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US9777066B2 (en) 2005-06-10 2017-10-03 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US11124576B2 (en) 2013-09-27 2021-09-21 Chungai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
US7635687B2 (en) * 1997-06-04 2009-12-22 Oxford Biomedica (Uk) Limited Vector system
WO1998055607A2 (en) 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Tumor targeted vector
JP2003515323A (ja) * 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
EP2161286A1 (en) * 1999-11-18 2010-03-10 Oxford Biomedica (UK) Limited Antibodies
US7402666B2 (en) 2000-11-13 2008-07-22 Oxford Biomedica (Uk) Ltd. Nucleotide encoding canine 5T4 antigen
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
AU2003259913A1 (en) * 2002-08-19 2004-03-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
TW200616662A (en) * 2004-09-10 2006-06-01 Wyeth Corp Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
GB0519303D0 (en) 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
KR20090069330A (ko) 2006-10-12 2009-06-30 와이어쓰 유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
KR100949791B1 (ko) * 2007-12-18 2010-03-30 이동기 오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
EP2313784B1 (en) * 2008-07-15 2015-02-18 Oxford BioMedica (UK) Limited Immunotherapeutic method
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
JP2011026294A (ja) * 2009-06-26 2011-02-10 Canon Inc 化合物
CA2846432A1 (en) * 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
BR112014018192A8 (pt) 2012-01-24 2021-03-02 Epic Sciences Inc método e kit para detecção de células tumorais circulantes 5t4-positivas, bem como métodos de diagnóstico de câncer 5t4-positivo e de seleção para atividade e eficácia de conjugado fármaco-anticorpo para tratamento de câncer
US20160304617A1 (en) 2013-06-17 2016-10-20 Asana Biosciences, Llc 5t4-targeted immunofusion molecule and methods
CN105813655B (zh) 2013-10-11 2022-03-15 阿萨纳生物科技有限责任公司 蛋白-聚合物-药物缀合物
CN105979970B (zh) 2013-10-11 2019-09-10 梅尔莎纳医疗公司 蛋白质-聚合物-药物共轭物
WO2016120331A1 (de) 2015-01-28 2016-08-04 Karl Sebastian Lang Agonistische anti-cd66cd66 antikörper für die antiviralen therapie
CN106749656B (zh) * 2016-11-11 2018-04-13 郑州师范学院 一种抗小鼠RCN3蛋白单克隆ScFv抗体及其淘选方法
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
KR102609624B1 (ko) 2017-03-15 2023-12-05 옥스포드 바이오메디카(유케이) 리미티드 방법
CA3080429A1 (en) 2017-11-01 2019-05-09 Nantbio, Inc. Il8 blocking emt pathway and overcoming cancer stem cells
US11638760B2 (en) 2017-11-27 2023-05-02 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
EP3727463A1 (en) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CN120795158A (zh) 2018-03-12 2025-10-17 健玛保 抗体
CA3117050A1 (en) 2018-10-29 2020-05-07 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
AU2024238898A1 (en) 2023-03-22 2025-10-16 Salubris Biotherapeutics, Inc. Anti-5t4 antigen binding domains, antibody-drug conjugates and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510642A (ja) * 1993-05-12 1996-11-12 ゾマ コーポレイション ゲロニンおよび抗体から成る免疫毒素
JPH10174587A (ja) * 1996-06-07 1998-06-30 Takeda Chem Ind Ltd 新規ペプチド、その製造法および用途
WO1998055607A2 (en) 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Tumor targeted vector
JPH1156368A (ja) * 1997-08-27 1999-03-02 Nippon Seibutsu Kagaku Kenkyusho 猫トロンボポエチンの活性を有する因子
JPH11504212A (ja) * 1995-04-19 1999-04-20 インサイト・ファーマスーティカルズ・インコーポレイテッド 新規なカテプシンｃホモログ
JPH11506920A (ja) * 1995-06-06 1999-06-22 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 結腸特異的遺伝子およびタンパク質

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481051A (en) * 1969-02-06 1969-12-02 Paramount Packaging Corp Heating apparatus
US4009778A (en) * 1975-11-04 1977-03-01 The Kartridg Pak Co. Dual compartment package and method for making same
US4267768A (en) * 1976-09-20 1981-05-19 David M. Cieslak Process for fabricating a reclosable bag
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
EP0336562B1 (en) * 1988-03-04 1995-06-14 Cancer Research Campaign Technology Ltd. Improvements relating to antigens
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5060146A (en) 1988-04-08 1991-10-22 International Business Machines Corporation Multilingual indexing system for alphabetical lysorting by comparing character weights and ascii codes
JPH04500308A (ja) 1989-05-17 1992-01-23 リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド 組換え型生成物のレトロウィルス媒介分泌
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
EP0621338A3 (en) * 1993-04-21 1997-10-29 Ajinomoto Kk The interleukin-2 response blocking immunosuppressor.
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
DE69523857T2 (de) * 1994-09-16 2002-06-13 Merck Patent Gmbh Immunokonjugate
GB9423085D0 (en) 1994-11-16 1995-01-04 Stringer Bradley M J Targeted T lymphocytes
US5824762A (en) * 1994-11-28 1998-10-20 Dow Corning Toray Silicone Co., Ltd. Organopolysiloxane and method for the preparation of the same
WO1996030504A1 (en) 1995-03-24 1996-10-03 Genetic Therapy, Inc. Modified viral envelope polypeptide
FR2732348B1 (fr) 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
DE19531346A1 (de) * 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen
WO1997017090A1 (en) 1995-11-07 1997-05-15 Baylor College Of Medicine Adenovirus-mediated production of bioactive proteins by mammalian cells and animals
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
CZ353698A3 (cs) * 1996-05-04 1999-02-17 Zeneca Limited Monoklonální protilátka proti CEA, konjugáty, které ji obsahují, způsob jejich přípravy a farmaceutický přípravek, který je obsahuje
WO1998012227A1 (en) * 1996-09-19 1998-03-26 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
US6348584B1 (en) * 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
JP2002505341A (ja) * 1998-03-06 2002-02-19 オックスフォード バイオメディカ（ユーケイ）リミテッド プロドラッグの活性化の増強
EP1160323A1 (en) * 1998-11-18 2001-12-05 Oxford Biomedica (UK) Limited 5T4 tumour-associated antigen for use in tumour immunotherapy
EP2161286A1 (en) * 1999-11-18 2010-03-10 Oxford Biomedica (UK) Limited Antibodies
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510642A (ja) * 1993-05-12 1996-11-12 ゾマ コーポレイション ゲロニンおよび抗体から成る免疫毒素
JPH11504212A (ja) * 1995-04-19 1999-04-20 インサイト・ファーマスーティカルズ・インコーポレイテッド 新規なカテプシンｃホモログ
JPH11506920A (ja) * 1995-06-06 1999-06-22 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 結腸特異的遺伝子およびタンパク質
JPH10174587A (ja) * 1996-06-07 1998-06-30 Takeda Chem Ind Ltd 新規ペプチド、その製造法および用途
WO1998055607A2 (en) 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Tumor targeted vector
JPH1156368A (ja) * 1997-08-27 1999-03-02 Nippon Seibutsu Kagaku Kenkyusho 猫トロンボポエチンの活性を有する因子

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
JPN6010051346; Ｊ．　Ｂ．　Ｃ．，　１９９４，　Ｖｏｌ．２６９，　ｐ．９３１９-９３２４ *
JPN6012046568; 金光修: 抗体工学入門 , 1994, ｐｐ．１４５-１６６，２１４-２１６, 株式会社地人書館 *
JPN6012046570; Ｂｒ．　Ｊ．　Ｃａｎｃｅｒ Ｖｏｌ．６１, 1990, ｐｐ．８９-９５ *
JPN6012046571; Ｂｒ．　Ｊ．　Ｃａｎｃｅｒ Ｖｏｌ．６１, 1990, ｐｐ．９６-１００ *
JPN6012046572; Ｂｒ．　Ｊ．　Ｃａｎｃｅｒ Ｖｏｌ．６９, 1994, ｐｐ．８９９-９０２ *
JPN6015004972; ＩＭＭＵＮＯＬＯＧＹ ９５（ＳＵＰＰＬ．１）, 1998, ９２　ＯＰ５２，ＯＰ５３
JPN6015004973; Ｊ．　ＢＩＯＬ．　ＣＨＥＭ． ２７２（１９）, 1997, １２４３０-１２４３６
JPN6015004974; ＧＥＮＥ １５９, 1995, ７３-８０
JPN6015004975; ＣＬＩＮＩＣＡＬ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ ２, 1996, １５２３-１５３１
JPN6015004976; ＪＯＵＲＮＡＬ　ＯＦ　ＢＩＯＴＥＣＨＮＯＬＯＧＹ ５３, 1997, ３-１２

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
US7993642B2 (en) 2003-12-12 2011-08-09 Chugai Seiyaku Kabushiki Kaisha Anti-MPL antibodies
US8008073B2 (en) 2003-12-12 2011-08-30 Chugai Seiyaku Kabushiki Kaisha Anti-Mpl antibodies
JP2008506389A (ja) * 2004-07-13 2008-03-06 セル ジェネシス インコーポレイテッド Ａａｖベクター組成物および免疫グロブリンの発現の増強のための方法ならびにその使用方法
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
US11168344B2 (en) 2005-03-31 2021-11-09 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US9777066B2 (en) 2005-06-10 2017-10-03 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
WO2006132352A1 (ja) * 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2を含有する医薬組成物
US8945543B2 (en) 2005-06-10 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US10934344B2 (en) 2006-03-31 2021-03-02 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US11124576B2 (en) 2013-09-27 2021-09-21 Chungai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
WO2015133484A1 (ja) * 2014-03-04 2015-09-11 国立大学法人徳島大学 腎臓疾患に関するマーカー及びその利用
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide

Also Published As

Publication number Publication date
US7074909B2 (en) 2006-07-11
US20060014222A1 (en) 2006-01-19
US20070259400A1 (en) 2007-11-08
US7514546B2 (en) 2009-04-07
US20100040539A1 (en) 2010-02-18
EP1242456A2 (en) 2002-09-25
WO2001036486A2 (en) 2001-05-25
CA2391925A1 (en) 2001-05-25
EP1242456B1 (en) 2008-10-15
US20110052577A1 (en) 2011-03-03
WO2001036486A3 (en) 2002-05-10
CN1423660A (zh) 2003-06-11
AU1290001A (en) 2001-05-30

Similar Documents

Publication Publication Date Title
JP2003515323A (ja) 抗 体
JP7773975B2 (ja) 抗ｐｄ－ｌ１単一ドメイン抗体ならびにその誘導体および使用
US11466085B2 (en) Anti-PD-L1 nanobody, coding sequence and use thereof
KR102710963B1 (ko) 항b7-h3의 모노클로널 항체 및 그가 세포 치료 중에서의 응용
KR102037016B1 (ko) 항 pd-l1 나노 항체 및 이의 응용
EP4582449A1 (en) Recombinant humanized monoclonal antibody targeting human gprc5d and application thereof
US20190352409A1 (en) Chimeric antigen receptor
TW201636425A (zh) 治療癌症之方法和組成物
JP2000502562A (ja) 細胞活性化プロセスおよびそのための試薬
KR20090078339A (ko) 암의 예방·치료제
JP2025063141A (ja) 抗ｈＫ２キメラ抗原受容体（ＣＡＲ）
JP7512413B2 (ja) 抗ｐｄ－ｌ１およびｐｄ－ｌ２抗体ならびにその誘導体および用途
CN114249832B (zh) 一种靶向cpsg4的人源化嵌合抗原受体及表达该嵌合抗原受体的免疫效应细胞及其应用
KR20210143097A (ko) Cd22에 특이적인 항체 및 이의 용도
JP2024505428A (ja) Ｈｅｒ２単一ドメイン抗体バリアントおよびそのｃａｒ
US20070161080A1 (en) Antibodies
CN115304680B (zh) 基于Pep42构建的双特异性细胞接合器分子的制备及其应用
KR102393776B1 (ko) Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체
JP2001522589A (ja) ミエリン乏突起膠細胞糖タンパク質ファミリーの新規タンパク質メンバーである、ｂｍｏｇおよびその免疫調節目的のための使用
TW200840825A (en) Prophylactic and therapeutic agent for cancers
US20250136695A1 (en) Development of novel pdl1 single-domain antibody
EP4257608A1 (en) Antibody specific for cd47 and use thereof
EP4159760A1 (en) Antibody specific to cd22, and use thereof
WO2025218621A1 (zh) 靶向muc1的抗原结合蛋白
HK40088437B (zh) 抗cd70纳米抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110404

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111102

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121120

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150511